× We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click our cookies policy for information on how to change your cookie settings.


meta|Evidence - COVID-19

Living meta-analysis and evidence synthesis of therapies for COVID19

tutorial video
En     Fr

Our approach
   
insufficient data

Interactive explorer of NMA results

baricitinib vs. casirivimab/imdevimab (Ronapreve) 1.03 [0.88; 1.22]1.03 [0.88;1.22]baricitinib vs. casirivimab/imdevimab (Ronapreve) 1.03 [0.88; 1.22]baricitinib vs. control baricitinib better 0.80 [0.72; 0.90]0.80 [0.72;0.90]baricitinib vs. control baricitinib better 0.80 [0.72; 0.90]baricitinib vs. convalescent plasma treatment baricitinib better 0.82 [0.73; 0.93]0.82 [0.73;0.93]baricitinib vs. convalescent plasma treatment baricitinib better 0.82 [0.73; 0.93]baricitinib vs. corticosteroids baricitinib better 0.85 [0.75; 0.95]0.85 [0.75;0.95]baricitinib vs. corticosteroids baricitinib better 0.85 [0.75; 0.95]baricitinib vs. interferon baricitinib better 0.73 [0.59; 0.89]0.73 [0.59;0.89]baricitinib vs. interferon baricitinib better 0.73 [0.59; 0.89]baricitinib vs. remdesivir 0.90 [0.75; 1.08]0.90 [0.75;1.08]baricitinib vs. remdesivir 0.90 [0.75; 1.08]baricitinib vs. sarilumab 0.90 [0.52; 1.57]0.90 [0.52;1.57]baricitinib vs. sarilumab 0.90 [0.52; 1.57]baricitinib vs. tocilizumab 0.95 [0.83; 1.09]0.95 [0.83;1.09]baricitinib vs. tocilizumab 0.95 [0.83; 1.09]baricitinib vs. tofacitinib 1.64 [0.50; 5.44]1.64 [0.50;5.44]baricitinib vs. tofacitinib 1.64 [0.50; 5.44]casirivimab/imdevimab (Ronapreve) vs. baricitinib 0.97 [0.82; 1.14]0.97 [0.82;1.14]casirivimab/imdevimab (Ronapreve) vs. baricitinib 0.97 [0.82; 1.14]casirivimab/imdevimab (Ronapreve) vs. control casirivimab/imdevimab (Ronapreve) better 0.78 [0.69; 0.88]0.78 [0.69;0.88]casirivimab/imdevimab (Ronapreve) vs. control casirivimab/imdevimab (Ronapreve) better 0.78 [0.69; 0.88]casirivimab/imdevimab (Ronapreve) vs. convalescent plasma treatment casirivimab/imdevimab (Ronapreve) better 0.80 [0.69; 0.92]0.80 [0.69;0.92]casirivimab/imdevimab (Ronapreve) vs. convalescent plasma treatment casirivimab/imdevimab (Ronapreve) better 0.80 [0.69; 0.92]casirivimab/imdevimab (Ronapreve) vs. corticosteroids casirivimab/imdevimab (Ronapreve) better 0.82 [0.72; 0.93]0.82 [0.72;0.93]casirivimab/imdevimab (Ronapreve) vs. corticosteroids casirivimab/imdevimab (Ronapreve) better 0.82 [0.72; 0.93]casirivimab/imdevimab (Ronapreve) vs. interferon casirivimab/imdevimab (Ronapreve) better 0.70 [0.57; 0.87]0.70 [0.57;0.87]casirivimab/imdevimab (Ronapreve) vs. interferon casirivimab/imdevimab (Ronapreve) better 0.70 [0.57; 0.87]casirivimab/imdevimab (Ronapreve) vs. remdesivir 0.87 [0.72; 1.05]0.87 [0.72;1.05]casirivimab/imdevimab (Ronapreve) vs. remdesivir 0.87 [0.72; 1.05]casirivimab/imdevimab (Ronapreve) vs. sarilumab 0.87 [0.50; 1.52]0.87 [0.50;1.52]casirivimab/imdevimab (Ronapreve) vs. sarilumab 0.87 [0.50; 1.52]casirivimab/imdevimab (Ronapreve) vs. tocilizumab 0.92 [0.79; 1.07]0.92 [0.79;1.07]casirivimab/imdevimab (Ronapreve) vs. tocilizumab 0.92 [0.79; 1.07]casirivimab/imdevimab (Ronapreve) vs. tofacitinib 1.59 [0.48; 5.27]1.59 [0.48;5.27]casirivimab/imdevimab (Ronapreve) vs. tofacitinib 1.59 [0.48; 5.27]control vs. baricitinib baricitinib better 1.24 [1.12; 1.39]1.24 [1.12;1.39]control vs. baricitinib baricitinib better 1.24 [1.12; 1.39]control vs. casirivimab/imdevimab (Ronapreve) casirivimab/imdevimab (Ronapreve) better 1.28 [1.13; 1.45]1.28 [1.13;1.45]control vs. casirivimab/imdevimab (Ronapreve) casirivimab/imdevimab (Ronapreve) better 1.28 [1.13; 1.45]control vs. convalescent plasma treatment 1.02 [0.96; 1.09]1.02 [0.96;1.09]control vs. convalescent plasma treatment 1.02 [0.96; 1.09]control vs. corticosteroids corticosteroids better 1.05 [1.01; 1.10]1.05 [1.01;1.10]control vs. corticosteroids corticosteroids better 1.05 [1.01; 1.10]control vs. interferon 0.90 [0.76; 1.08]0.90 [0.76;1.08]control vs. interferon 0.90 [0.76; 1.08]control vs. remdesivir 1.12 [0.97; 1.29]1.12 [0.97;1.29]control vs. remdesivir 1.12 [0.97; 1.29]control vs. sarilumab 1.12 [0.65; 1.93]1.12 [0.65;1.93]control vs. sarilumab 1.12 [0.65; 1.93]control vs. tocilizumab tocilizumab better 1.18 [1.08; 1.29]1.18 [1.08;1.29]control vs. tocilizumab tocilizumab better 1.18 [1.08; 1.29]control vs. tofacitinib 2.04 [0.62; 6.73]2.04 [0.62;6.73]control vs. tofacitinib 2.04 [0.62; 6.73]convalescent plasma treatment vs. baricitinib baricitinib better 1.21 [1.07; 1.37]1.21 [1.07;1.37]convalescent plasma treatment vs. baricitinib baricitinib better 1.21 [1.07; 1.37]convalescent plasma treatment vs. casirivimab/imdevimab (Ronapreve) casirivimab/imdevimab (Ronapreve) better 1.25 [1.09; 1.44]1.25 [1.09;1.44]convalescent plasma treatment vs. casirivimab/imdevimab (Ronapreve) casirivimab/imdevimab (Ronapreve) better 1.25 [1.09; 1.44]convalescent plasma treatment vs. control 0.98 [0.92; 1.04]0.98 [0.92;1.04]convalescent plasma treatment vs. control 0.98 [0.92; 1.04]convalescent plasma treatment vs. corticosteroids 1.03 [0.95; 1.11]1.03 [0.95;1.11]convalescent plasma treatment vs. corticosteroids 1.03 [0.95; 1.11]convalescent plasma treatment vs. interferon 0.88 [0.73; 1.06]0.88 [0.73;1.06]convalescent plasma treatment vs. interferon 0.88 [0.73; 1.06]convalescent plasma treatment vs. remdesivir 1.09 [0.94; 1.28]1.09 [0.94;1.28]convalescent plasma treatment vs. remdesivir 1.09 [0.94; 1.28]convalescent plasma treatment vs. sarilumab 1.10 [0.64; 1.89]1.10 [0.64;1.89]convalescent plasma treatment vs. sarilumab 1.10 [0.64; 1.89]convalescent plasma treatment vs. tocilizumab tocilizumab better 1.15 [1.04; 1.29]1.15 [1.04;1.29]convalescent plasma treatment vs. tocilizumab tocilizumab better 1.15 [1.04; 1.29]convalescent plasma treatment vs. tofacitinib 1.99 [0.60; 6.58]1.99 [0.60;6.58]convalescent plasma treatment vs. tofacitinib 1.99 [0.60; 6.58]corticosteroids vs. baricitinib baricitinib better 1.18 [1.05; 1.33]1.18 [1.05;1.33]corticosteroids vs. baricitinib baricitinib better 1.18 [1.05; 1.33]corticosteroids vs. casirivimab/imdevimab (Ronapreve) casirivimab/imdevimab (Ronapreve) better 1.22 [1.07; 1.39]1.22 [1.07;1.39]corticosteroids vs. casirivimab/imdevimab (Ronapreve) casirivimab/imdevimab (Ronapreve) better 1.22 [1.07; 1.39]corticosteroids vs. control corticosteroids better 0.95 [0.91; 0.99]0.95 [0.91;0.99]corticosteroids vs. control corticosteroids better 0.95 [0.91; 0.99]corticosteroids vs. convalescent plasma treatment 0.97 [0.90; 1.05]0.97 [0.90;1.05]corticosteroids vs. convalescent plasma treatment 0.97 [0.90; 1.05]corticosteroids vs. interferon 0.86 [0.72; 1.03]0.86 [0.72;1.03]corticosteroids vs. interferon 0.86 [0.72; 1.03]corticosteroids vs. remdesivir 1.07 [0.92; 1.24]1.07 [0.92;1.24]corticosteroids vs. remdesivir 1.07 [0.92; 1.24]corticosteroids vs. sarilumab 1.07 [0.62; 1.84]1.07 [0.62;1.84]corticosteroids vs. sarilumab 1.07 [0.62; 1.84]corticosteroids vs. tocilizumab tocilizumab better 1.12 [1.02; 1.24]1.12 [1.02;1.24]corticosteroids vs. tocilizumab tocilizumab better 1.12 [1.02; 1.24]corticosteroids vs. tofacitinib 1.94 [0.59; 6.40]1.94 [0.59;6.40]corticosteroids vs. tofacitinib 1.94 [0.59; 6.40]interferon vs. baricitinib baricitinib better 1.38 [1.12; 1.70]1.38 [1.12;1.70]interferon vs. baricitinib baricitinib better 1.38 [1.12; 1.70]interferon vs. casirivimab/imdevimab (Ronapreve) casirivimab/imdevimab (Ronapreve) better 1.42 [1.14; 1.77]1.42 [1.14;1.77]interferon vs. casirivimab/imdevimab (Ronapreve) casirivimab/imdevimab (Ronapreve) better 1.42 [1.14; 1.77]interferon vs. control 1.11 [0.93; 1.32]1.11 [0.93;1.32]interferon vs. control 1.11 [0.93; 1.32]interferon vs. convalescent plasma treatment 1.13 [0.94; 1.37]1.13 [0.94;1.37]interferon vs. convalescent plasma treatment 1.13 [0.94; 1.37]interferon vs. corticosteroids 1.16 [0.97; 1.40]1.16 [0.97;1.40]interferon vs. corticosteroids 1.16 [0.97; 1.40]interferon vs. remdesivir 1.24 [0.99; 1.56]1.24 [0.99;1.56]interferon vs. remdesivir 1.24 [0.99; 1.56]interferon vs. sarilumab 1.24 [0.70; 2.20]1.24 [0.70;2.20]interferon vs. sarilumab 1.24 [0.70; 2.20]interferon vs. tocilizumab tocilizumab better 1.31 [1.07; 1.60]1.31 [1.07;1.60]interferon vs. tocilizumab tocilizumab better 1.31 [1.07; 1.60]interferon vs. tofacitinib 2.26 [0.68; 7.55]2.26 [0.68;7.55]interferon vs. tofacitinib 2.26 [0.68; 7.55]remdesivir vs. baricitinib 1.11 [0.93; 1.33]1.11 [0.93;1.33]remdesivir vs. baricitinib 1.11 [0.93; 1.33]remdesivir vs. casirivimab/imdevimab (Ronapreve) 1.15 [0.95; 1.39]1.15 [0.95;1.39]remdesivir vs. casirivimab/imdevimab (Ronapreve) 1.15 [0.95; 1.39]remdesivir vs. control 0.89 [0.77; 1.03]0.89 [0.77;1.03]remdesivir vs. control 0.89 [0.77; 1.03]remdesivir vs. convalescent plasma treatment 0.91 [0.78; 1.07]0.91 [0.78;1.07]remdesivir vs. convalescent plasma treatment 0.91 [0.78; 1.07]remdesivir vs. corticosteroids 0.94 [0.81; 1.09]0.94 [0.81;1.09]remdesivir vs. corticosteroids 0.94 [0.81; 1.09]remdesivir vs. interferon 0.81 [0.64; 1.01]0.81 [0.64;1.01]remdesivir vs. interferon 0.81 [0.64; 1.01]remdesivir vs. sarilumab 1.00 [0.57; 1.76]1.00 [0.57;1.76]remdesivir vs. sarilumab 1.00 [0.57; 1.76]remdesivir vs. tocilizumab 1.06 [0.89; 1.25]1.06 [0.89;1.25]remdesivir vs. tocilizumab 1.06 [0.89; 1.25]remdesivir vs. tofacitinib 1.82 [0.55; 6.06]1.82 [0.55;6.06]remdesivir vs. tofacitinib 1.82 [0.55; 6.06]sarilumab vs. baricitinib 1.11 [0.64; 1.92]1.11 [0.64;1.92]sarilumab vs. baricitinib 1.11 [0.64; 1.92]sarilumab vs. casirivimab/imdevimab (Ronapreve) 1.14 [0.66; 1.99]1.14 [0.66;1.99]sarilumab vs. casirivimab/imdevimab (Ronapreve) 1.14 [0.66; 1.99]sarilumab vs. control 0.89 [0.52; 1.53]0.89 [0.52;1.53]sarilumab vs. control 0.89 [0.52; 1.53]sarilumab vs. convalescent plasma treatment 0.91 [0.53; 1.57]0.91 [0.53;1.57]sarilumab vs. convalescent plasma treatment 0.91 [0.53; 1.57]sarilumab vs. corticosteroids 0.94 [0.54; 1.61]0.94 [0.54;1.61]sarilumab vs. corticosteroids 0.94 [0.54; 1.61]sarilumab vs. interferon 0.80 [0.45; 1.42]0.80 [0.45;1.42]sarilumab vs. interferon 0.80 [0.45; 1.42]sarilumab vs. remdesivir 1.00 [0.57; 1.75]1.00 [0.57;1.75]sarilumab vs. remdesivir 1.00 [0.57; 1.75]sarilumab vs. tocilizumab 1.05 [0.61; 1.82]1.05 [0.61;1.82]sarilumab vs. tocilizumab 1.05 [0.61; 1.82]sarilumab vs. tofacitinib 1.82 [0.49; 6.74]1.82 [0.49;6.74]sarilumab vs. tofacitinib 1.82 [0.49; 6.74]tocilizumab vs. baricitinib 1.05 [0.91; 1.21]1.05 [0.91;1.21]tocilizumab vs. baricitinib 1.05 [0.91; 1.21]tocilizumab vs. casirivimab/imdevimab (Ronapreve) 1.09 [0.93; 1.27]1.09 [0.93;1.27]tocilizumab vs. casirivimab/imdevimab (Ronapreve) 1.09 [0.93; 1.27]tocilizumab vs. control tocilizumab better 0.85 [0.77; 0.92]0.85 [0.77;0.92]tocilizumab vs. control tocilizumab better 0.85 [0.77; 0.92]tocilizumab vs. convalescent plasma treatment tocilizumab better 0.87 [0.78; 0.96]0.87 [0.78;0.96]tocilizumab vs. convalescent plasma treatment tocilizumab better 0.87 [0.78; 0.96]tocilizumab vs. corticosteroids tocilizumab better 0.89 [0.81; 0.98]0.89 [0.81;0.98]tocilizumab vs. corticosteroids tocilizumab better 0.89 [0.81; 0.98]tocilizumab vs. interferon tocilizumab better 0.76 [0.63; 0.93]0.76 [0.63;0.93]tocilizumab vs. interferon tocilizumab better 0.76 [0.63; 0.93]tocilizumab vs. remdesivir 0.95 [0.80; 1.12]0.95 [0.80;1.12]tocilizumab vs. remdesivir 0.95 [0.80; 1.12]tocilizumab vs. sarilumab 0.95 [0.55; 1.64]0.95 [0.55;1.64]tocilizumab vs. sarilumab 0.95 [0.55; 1.64]tocilizumab vs. tofacitinib 1.73 [0.52; 5.71]1.73 [0.52;5.71]tocilizumab vs. tofacitinib 1.73 [0.52; 5.71]tofacitinib vs. baricitinib 0.61 [0.18; 2.02]0.61 [0.18;2.02]tofacitinib vs. baricitinib 0.61 [0.18; 2.02]tofacitinib vs. casirivimab/imdevimab (Ronapreve) 0.63 [0.19; 2.09]0.63 [0.19;2.09]tofacitinib vs. casirivimab/imdevimab (Ronapreve) 0.63 [0.19; 2.09]tofacitinib vs. control 0.49 [0.15; 1.62]0.49 [0.15;1.62]tofacitinib vs. control 0.49 [0.15; 1.62]tofacitinib vs. convalescent plasma treatment 0.50 [0.15; 1.66]0.50 [0.15;1.66]tofacitinib vs. convalescent plasma treatment 0.50 [0.15; 1.66]tofacitinib vs. corticosteroids 0.52 [0.16; 1.70]0.52 [0.16;1.70]tofacitinib vs. corticosteroids 0.52 [0.16; 1.70]tofacitinib vs. interferon 0.44 [0.13; 1.48]0.44 [0.13;1.48]tofacitinib vs. interferon 0.44 [0.13; 1.48]tofacitinib vs. remdesivir 0.55 [0.17; 1.82]0.55 [0.17;1.82]tofacitinib vs. remdesivir 0.55 [0.17; 1.82]tofacitinib vs. sarilumab 0.55 [0.15; 2.04]0.55 [0.15;2.04]tofacitinib vs. sarilumab 0.55 [0.15; 2.04]tofacitinib vs. tocilizumab 0.58 [0.18; 1.92]0.58 [0.18;1.92]tofacitinib vs. tocilizumab 0.58 [0.18; 1.92]Risk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNcorticosteroidsRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNremdesivirRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNconvalescent plasma treatmentRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNbaricitinibRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNtofacitinibRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNcasirivimab/imdevimab (Ronapreve)Risk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNinterferonRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNtocilizumab Risk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNsarilumabRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNcontroldirect evidencenetwork meta-analysis ROB:highsome concernslowNA

Click on treatment name to display related network evidence

T vs. C corticosteroidsremdesivirconvalescent plasma treatmentbaricitinibtofacitinibcasirivimab/imdevimab (Ronapreve)interferontocilizumab sarilumabcontrol
corticosteroids---1.07
0.92; 1.24		0.97
0.90; 1.05		1.18
1.05; 1.33		1.94
0.59; 6.40		1.22
1.07; 1.39		0.86
0.72; 1.03		1.12
1.02; 1.24		1.07
0.62; 1.84		0.95
0.91; 0.99
remdesivir0.94
0.81; 1.09		---0.91
0.78; 1.07		1.11
0.93; 1.33		1.82
0.55; 6.06		1.15
0.95; 1.39		0.81
0.64; 1.01		1.06
0.89; 1.25		1.00
0.57; 1.76		0.89
0.77; 1.03
convalescent plasma treatment1.03
0.95; 1.11		1.09
0.94; 1.28		---1.21
1.07; 1.37		1.99
0.60; 6.58		1.25
1.09; 1.44		0.88
0.73; 1.06		1.15
1.04; 1.29		1.10
0.64; 1.89		0.98
0.92; 1.04
baricitinib0.85
0.75; 0.95		0.90
0.75; 1.08		0.82
0.73; 0.93		---1.64
0.50; 5.44		1.03
0.88; 1.22		0.73
0.59; 0.89		0.95
0.83; 1.09		0.90
0.52; 1.57		0.80
0.72; 0.90
tofacitinib0.52
0.16; 1.70		0.55
0.17; 1.82		0.50
0.15; 1.66		0.61
0.18; 2.02		---0.63
0.19; 2.09		0.44
0.13; 1.48		0.58
0.18; 1.92		0.55
0.15; 2.04		0.49
0.15; 1.62
casirivimab/imdevimab (Ronapreve)0.82
0.72; 0.93		0.87
0.72; 1.05		0.80
0.69; 0.92		0.97
0.82; 1.14		1.59
0.48; 5.27		---0.70
0.57; 0.87		0.92
0.79; 1.07		0.87
0.50; 1.52		0.78
0.69; 0.88
interferon1.16
0.97; 1.40		1.24
0.99; 1.56		1.13
0.94; 1.37		1.38
1.12; 1.70		2.26
0.68; 7.55		1.42
1.14; 1.77		---1.31
1.07; 1.60		1.24
0.70; 2.20		1.11
0.93; 1.32
tocilizumab 0.89
0.81; 0.98		0.95
0.80; 1.12		0.87
0.78; 0.96		1.05
0.91; 1.21		1.73
0.52; 5.71		1.09
0.93; 1.27		0.76
0.63; 0.93		---0.95
0.55; 1.64		0.85
0.77; 0.92
sarilumab0.94
0.54; 1.61		1.00
0.57; 1.75		0.91
0.53; 1.57		1.11
0.64; 1.92		1.82
0.49; 6.74		1.14
0.66; 1.99		0.80
0.45; 1.42		1.05
0.61; 1.82		---0.89
0.52; 1.53
control1.05
1.01; 1.10		1.12
0.97; 1.29		1.02
0.96; 1.09		1.24
1.12; 1.39		2.04
0.62; 6.73		1.28
1.13; 1.45		0.90
0.76; 1.08		1.18
1.08; 1.29		1.12
0.65; 1.93		---

This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.

   

- About - Our approach - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons